Idaho Medicaid and tirzepatide
Idaho Medicaid did not cover GLP-1s for weight loss as of January 2026, according to KFF, though it must cover them for type 2 diabetes.
In 2025 Idaho Medicaid paid for 12,492 tirzepatide prescriptions (Mounjaro, Zepbound), 27% of its GLP-1 prescriptions and 32nd of the 50 states and DC. It reimbursed $13.0 million before rebates, $1,037 a prescription against $1,032 nationally.
| Brand | Prescriptions | Medicaid paid | Per Rx |
|---|---|---|---|
| Mounjaro | 10,823 | $11.2 million | $1,035 |
| Zepbound | 1,669 | $1.8 million | $1,055 |
Tirzepatide in the states around Idaho
| State | Sell tirzepatide, ship there | Cheapest | Medicaid Rx, 2025 | Medicaid, Zepbound for weight loss |
|---|---|---|---|---|
| Idaho | 17 | $69/moWellmedr | 12,492 | Medicaid Zepbound: Not covered (KFF) |
| Montana | 17 | $69/moWellmedr | 2,904 | Medicaid Zepbound: No |
| Nevada | 17 | $69/moWellmedr | 19,540 | Medicaid Zepbound: No |
| Oregon | 17 | $69/moWellmedr | 8,571 | Medicaid Zepbound: No |
| Utah | 17 | $69/moWellmedr | 8,455 | Medicaid Zepbound: Not confirmed (KFF) |
| Washington | 16 | $69/moWellmedr | 23,929 | Medicaid Zepbound: No |
| Wyoming | 17 | $69/moWellmedr | 738 | Medicaid Zepbound: No |



